The Challenge: Effective Nucleic Acid Delivery

Recent advances in the development of high precision nucleic acid therapies have put cures in reach for previously untreatable diseases and conditions. Therapies in development have the potential to eradicate genetic diseases, block cancer and reverse aging.

However, these therapies all face the same challenge; delivery of genetic payloads directly into target cells with no significant toxicity. Gene therapy-clinical trials using cationic or ionizable lipid nanoparticle platforms have been disappointing due to high toxicity and an inability to target organs other than the liver.

Entos Pharmaceuticals

The Solution

Entos' Fusogenix Platform

Fusogenix is formulated with well-tolerated neutral lipids and our proprietary FAST proteins (Fusion-Associated Small Transmembrane) that ensues highly efficient fusion and intracellular delivery of therapeutic nucleic acid payloads. Our Fusogenix platform combines the favorable low-toxicity profile of a neutral lipid formulation with the high efficacy of our fusogenic protein-mediated delivery technology.

Novel Platform:
Any Payload

Entos developed a library of Fusogenix formulations to effectively deliver a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi and CRISPR. The classes of health indications that can be addressed by Fusogenix is unlimited. Currently, Entos is involved in Oncology Therapeutics, DNA Vaccines, Anti-Virals, Gene Editing, Immunotherapy, and Senolytic therapies.

Well Tolerated Formulations

Fusogenix is safe and well tolerated at doses that far exceed the expected human efficacious dose. Tolerability studies show no adverse pathology, either within the principle uptake organs or the liver and spleen, even at very high doses.

FAST protein catalyzes rapid lipid mixing between the proteo-lipid vehicle (PLV) and target cell plasma membrane. PLV cargo is deposited directly into the cytoplasm – bypassing the endocytic pathway

Treatment & Application

Broad Biodistribution

Due to its favorable tolerability profile, Fusogenix has significant bioavailability in a wide variety of extra-hepatic tissues. This enables the delivery of therapeutic doses of nucleic acid medicines throughout the body.

Suitable for Repeat Dosing

Fusogenix is non-immunogenic, which allows for repeat dosing with no reduction in efficacy. These qualities make our platform ideal for long term treatment of healthy individuals.

Scalable Manufacturing

Entos utilizes a scalable microfluidic manufacturing process that allows for continuous production of highly homogeneous, reproducible, clinical grade material. Our high capacity single-step method enables the production of GMP drug substances with unprecedented precision.

Active Targeting

Fusogenix formulated with targeted FAST proteins can preferentially accumulate in tissues where they have maximum therapeutic impact.

Entos Pharmaceuticals

Next-Generation Nucleic Acid Delivery

Fusogenix uses a novel mechanism of action to deliver nucleic acids, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, siRNA, and CRISPR.

Success Through Partnership

We strive to be active partners in the upcoming transformation of healthcare with the development of innovative genetic personalized medicines.

Our Partners

Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.